# Neurovalens

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neurovalens

- Industry: Medical Devices & Equipment
- Headquarters: Belfast, UK
- Website: www.neurovalens.com/
- Total disclosed funding: $7.6M
- Latest round: Series A (Jan 15, 2019)
- Investors on record: 6

## About

Founded in 2013 and based in Belfast, UK, Neurovalens Limited operates as a medical technology company. The company was founded by its CEO, Jason McKeown, and Paul D. McGeoch. In August 2025, Neurovalens Limited raised GBP 7 million in equity and debt funding led by new investor Investment Fund for Northern Ireland, with participation from returning investors WhiteRock Capital Partners, IQ Capital, Innovation Ulster, and ACF Investors. Other unspecified investors also participated in the round. Neurovalens develops medical devices, mainly non-invasive neurostimulation products, to treat chronic insomnia and generalized anxiety disorder. The company plans to utilize the August 2025 funding to increase sales of its existing medical devices and pursue further approvals from US regulators.

## Funding rounds

- Series A, Jan 15, 2019, $6.2M — Clarendon Fund Managers, Wharton Asset Management, IQ Capital, ACF Investors, Techstart NI, Beltrae Partners
- Seed, Jul 19, 2017, $1.4M — ACF Investors, Techstart NI, Beltrae Partners

## Investors

- ACF Investors (https://capitalatlas.ai/funds/acf-investors) — Seed, Series A
- Techstart NI — Seed, Series A
- Beltrae Partners — Seed, Series A
- Clarendon Fund Managers (https://capitalatlas.ai/funds/clarendon-fund-managers) — Series A
- Wharton Asset Management — Series A
- IQ Capital (https://capitalatlas.ai/funds/iq-capital) — Series A